These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 30573499)

  • 1. Hypotensive efficacy of topical brimonidine for intraocular pressure spikes following intravitreal injections of antivascular endothelial growth factor agents: a randomised crossover trial.
    Felfeli T; Hostovsky A; Trussart R; Yan P; Brent MH; Mandelcorn ED
    Br J Ophthalmol; 2019 Oct; 103(10):1388-1394. PubMed ID: 30573499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections.
    Frenkel MP; Haji SA; Frenkel RE
    Arch Ophthalmol; 2010 Dec; 128(12):1523-7. PubMed ID: 21149773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Topical application of hypotensive drugs for the prevention of intraocular pressure elevation after intravitreal injections of anti-VEGF drugs].
    Andreeva YS; Alkharki L; Shelankova AV; Budzinskaya MV
    Vestn Oftalmol; 2024; 140(2. Vyp. 2):73-79. PubMed ID: 38739134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ASSOCIATION BETWEEN NEEDLE SIZE, POSTINJECTION REFLUX, AND INTRAOCULAR PRESSURE SPIKES AFTER INTRAVITREAL INJECTIONS.
    Pang CE; Mrejen S; Hoang QV; Sorenson JA; Freund KB
    Retina; 2015 Jul; 35(7):1401-6. PubMed ID: 25650712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment.
    Bressler SB; Almukhtar T; Bhorade A; Bressler NM; Glassman AR; Huang SS; Jampol LM; Kim JE; Melia M;
    JAMA Ophthalmol; 2015 May; 133(5):589-97. PubMed ID: 25719991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of acetazolamide, brimonidine, and anterior chamber paracentesis for ocular hypertension control after initial intravitreal bevacizumab injection: a randomized clinical trial.
    Katayama BY; Bonini-Filho MA; Messias AM; Paula JS; Martin LF; Costa R; Jorge R
    J Glaucoma; 2014 Sep; 23(7):461-3. PubMed ID: 23632404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of prophylactic medication and influence of vitreous reflux in pressure rise after intravitreal injections of anti-VEGF drugs.
    Carnota-Méndez P; Méndez-Vázquez C; Otero-Villar J; Saavedra-Pazos JA
    Eur J Ophthalmol; 2014; 24(5):771-7. PubMed ID: 24706353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EFFECT OF SERIAL ANTERIOR CHAMBER PARACENTESIS ON SUSTAINED INTRAOCULAR PRESSURE ELEVATION IN PATIENTS RECEIVING INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
    Sisk RA; Rusia D; Zamora BG; Kuley A; Toussaint BW
    Retina; 2019 Oct; 39(10):1959-1964. PubMed ID: 30234855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraocular Pressure in Eyes Receiving Intravitreal Antivascular Endothelial Growth Factor Injections.
    Lemos V; Cabugueira A; Noronha M; Abegão Pinto L; Reina M; Branco J; Gomes T
    Ophthalmologica; 2015; 233(3-4):162-8. PubMed ID: 25791262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The early effects of intravitreal anti vascular endothelial growth factor agents on intraocular pressure and central corneal thickness.
    Omay E; Elgin U; Sen E; Yilmazbas P
    Int Ophthalmol; 2016 Oct; 36(5):665-70. PubMed ID: 26780098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.
    Tseng JJ; Vance SK; Della Torre KE; Mendonca LS; Cooney MJ; Klancnik JM; Sorenson JA; Freund KB
    J Glaucoma; 2012; 21(4):241-7. PubMed ID: 21423038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib.
    Choi DY; Ortube MC; McCannel CA; Sarraf D; Hubschman JP; McCannel TA; Gorin MB
    Retina; 2011 Jun; 31(6):1028-35. PubMed ID: 21836409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term intraocular pressure trends following intravitreal ranibizumab injections for neovascular age-related macular degeneration-the role of oral acetazolamide in protecting glaucoma patients.
    Murray CD; Wood D; Allgar V; Walters G; Gale RP
    Eye (Lond); 2014 Oct; 28(10):1218-22. PubMed ID: 25081290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained intraocular pressure elevation in eyes treated with intravitreal injections of anti-vascular endothelial growth factor for diabetic macular edema in a real-life setting.
    Vo Kim S; Fajnkuchen F; Sarda V; Qu-Knafo L; Bodaghi B; Giocanti-Aurégan A
    Graefes Arch Clin Exp Ophthalmol; 2017 Nov; 255(11):2165-2171. PubMed ID: 28831613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic effect of brinzolamide-brimonidine fixed combination on intraocular pressure spikes after intravitreal anti-VEGF injections.
    Dettoraki M; Rapti E; Fragkos D; Theiopoulos I; Legaki A; Gkounta A; Anyfantaki D; Riga F
    Int Ophthalmol; 2021 Sep; 41(9):3191-3198. PubMed ID: 34114138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy.
    Hoang QV; Tsuang AJ; Gelman R; Mendonca LS; Della Torre KE; Jung JJ; Freund KB
    Retina; 2013 Jan; 33(1):179-87. PubMed ID: 22990314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraocular Pressure Changes in Non-Glaucomatous Patients Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Agents.
    Kiddee W; Montriwet M
    PLoS One; 2015; 10(9):e0137833. PubMed ID: 26360382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration.
    Mathalone N; Arodi-Golan A; Sar S; Wolfson Y; Shalem M; Lavi I; Geyer O
    Graefes Arch Clin Exp Ophthalmol; 2012 Oct; 250(10):1435-40. PubMed ID: 22434210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of brimonidine 0.2% in controlling acute postoperative intraocular pressure elevation after phacoemulsification.
    Katsimpris JM; Siganos D; Konstas AG; Kozobolis V; Georgiadis N
    J Cataract Refract Surg; 2003 Dec; 29(12):2288-94. PubMed ID: 14709288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effects of multiple intravitreal antivascular endothelial growth factor injections on intraocular pressure.
    Kim YJ; Sung KR; Lee KS; Joe SG; Lee JY; Kim JG; Yoon YH
    Am J Ophthalmol; 2014 Jun; 157(6):1266-1271.e1. PubMed ID: 24561173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.